Investor Relations LatestPress Releases Oct 17, 2024 Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV Oct 17, 2024 Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance Oct 10, 2024 Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024 btn News IR View All RecentEvents Oct 10, 2024 10 Oct 2024 at 8:30 AM EDT Third-Quarter Fiscal 2024 Financial Results Conference Call Listen to Webcast Jul 10, 2024 10 Jul 2024 at 8:30 AM EDT Second-Quarter Fiscal 2024 Financial Results Conference Call Listen to Webcast May 09, 2024 09 May 2024 at 10:00 AM EDT Annual Meeting of Shareholders Listen to Webcast btn Events View All Financial InformationLatest Earnings Show all Q3 2024 Financial Statement 639.2 KB MD&A 892.4 KB btn QRs View More PresentationsInvestor Presentation Download PDF
Oct 17, 2024 Theratechnologies IDWeek Presentations Highlight the Impact of Excess Visceral Abdominal Fat (EVAF) on Cardiovascular Disease (CVD) Risk in People with HIV
Oct 17, 2024 Theratechnologies Unveils Study Design and Baseline Characteristics of PROMISE-US Trial of Ibalizumab in Heavily Treatment-Experienced People with HIV and Multidrug Resistance
Oct 10, 2024 Theratechnologies Reports Strong Financial Results and Announces Positive Net Income for Third Quarter 2024
Oct 10, 2024 10 Oct 2024 at 8:30 AM EDT Third-Quarter Fiscal 2024 Financial Results Conference Call Listen to Webcast
Jul 10, 2024 10 Jul 2024 at 8:30 AM EDT Second-Quarter Fiscal 2024 Financial Results Conference Call Listen to Webcast